ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0409

Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size

Takashi Shimoyama1, Ken Uchino2, Leonard Calabrese3 and Rula Hajj-ali3, 1Nippon Medical School, Nippon, Japan, 2Cleveland Clinic, Cleveland, 3Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2020

Keywords: Imaging, Stroke, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Diagnosis of the central nervous system vasculitis (CNS-V) is made on the basis of image findings or brain biopsy. Recently, two different subtypes of the disease have been postulated, the small (SVV) and large-medium vessel variant (LMVV).   We hypothesized that the image profiles and diagnostic approaches would vary between the LMVV and the SVV in patients with CNS-V. The aim of this study was to clarify the clinical characteristics, brain MRI findings, and diagnostic accuracy for high-resolution vessel wall image (HR-VWI) and brain biopsy according to affected vessel size in CNS-V patients from our prospective CNS vasculopathy registry.

Methods: We extracted CNS-V patients from our prospective CNS vasculopathy registry (n=201) from 2012-2019. Arterial involvement was assessed by digital subtraction angiography (DSA) or MR angiography (MRA). LMVV was defined as patients with cerebral vasculature indicating vasculitis in proximal or middle arterial segments. SVV was diagnosed with vessel involvements in only smaller distal branch or normal angiography. We compared clinical demographics, MRI findings including high-resolution vessel wall image (HR-VWI), and diagnostic accuracy for brain biopsy between two variants.

Results: We identified 34 cases who underwent cerebral vascular studies (DSA: n=26, MRA: n=32). Among them, 11 (32.4%) were LMVV and 23 (67.6%) were SVV based on angiographical findings. LMVV had more infarcts (LMVV: 100.0 % vs. SVV: 60.9%, P=0.017) and were more likely to have concentric vessel wall enhancement on HR-VWI (LMVV: 90.0% (9/10) vs. SVV: 7.1% (1/14), P< 0.001);summary in Table1. 

By contrast, meningeal/parenchymal contrast enhancement lesion was more frequently observed in the SVV group (SVV: 87.0% vs. LMVV 45.5%, P=0.006) and the majority of SVV was diagnosed by brain biopsy (SVV: 78.3% vs. LMVV: 30.8%, P=0.022). The diagnostic accuracy of the brain biopsy was 100 % (18/18) in the SVV and 57.1% (4/7) in the LMVV, respectively (P=0.015);summary inTable 2.

Conclusion: Clinical and image characteristics of CNS-V seem to differ concerning the affected vessel size. LMVV is more likely to develop ischemic stroke and HR-VWI is useful for diagnosis of CNS-V with LMVV. Higher prevalence rate of mass lesion and leptomeningeal/parenchymal contrast enhancement lesion is associated with SVV; Brain biopsy is of high yield and thus should be considered in suspected CNS-V; higher yield of biopsy is associated with SVV variant but still positive in almost one third of LMVV variant

Brain MRI, cerebral angiogram, and HR-VWI findings between LMVV and SVV in CNS-V patients

Brain biopsy and CSF findings between LMVV and SVV in CNS-V patients


Disclosure: T. Shimoyama, None; K. Uchino, None; L. Calabrese, AbbVie, 1, 2, GlaxoSmithKline, 1, Bristol-Myers Squibb, 1, Genentech, 1, 2, Janssen, 1, 2, Novartis, 1, 2, Sanofi, 1, Horizon, 1, Crescendo, 1, Gilead, 1; R. Hajj-ali, ABBVIE, 1, Rockpoint, 1.

To cite this abstract in AMA style:

Shimoyama T, Uchino K, Calabrese L, Hajj-ali R. Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-brain-mri-findings-and-diagnostic-approach-of-the-central-nervous-system-vasculitis-by-affected-vessel-size/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-brain-mri-findings-and-diagnostic-approach-of-the-central-nervous-system-vasculitis-by-affected-vessel-size/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology